At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 211 enrolled
Drug / intervention
Half-boosted Fosamprenavir +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
See Detailed Description.
In Brief
A Phase 3 clinical trial evaluating Half-boosted Fosamprenavir and Full Boosted Fosamprenavir for HIV Infection and Infection, Human Immunodeficiency Virus. Completed, enrolled 211 participants across 51 sites in 2 countries.
Detailed Summary
This is a 24-week study to evaluate the efficacy and safety of a once-daily ritonavir-boosted fosamprenavir regimen (1400mg/100mg QD) to a 200mg ritonavir-boosted fosamprenavir regimen administered either twice-daily or once-daily.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesPuerto Rico, United States
Collaborators--
Timeline
Phase 3CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartMay 2006
First PostedAug 2006
Primary CompletionJun 2008
TodayJul 2026
First PostedAug 15, 2006
Enrollment StartMay 1, 2006
Primary CompletionJun 1, 2008
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 19.9 years ago
Interventions
Half-boosted Fosamprenavirdrug
Once daily, reduced dose ritonavir-boosted fosamprenavir
Full Boosted Fosamprenavirdrug
Full ritonavir-boosted fosamprenavir